Skip to main content

Table 2 Univariate analysis of factors affecting survival.

From: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

Factor

Category

Event

Median OS

95% CI

p value

Age (years)

<58

44

6.7 m

6.0 - 7.4

0.41

 

≥58

47

6.2 m

3.2 - 9.3

 

Gender

Male

67

6.6 m

5.7 - 7.5

0.83

 

Female

24

6.4 m

2.5 - 10.4

 

ECOG PS

0/1

54

7.2 m

6.0 - 8.4

<0.01

 

2/3

33

4.5 m

3.3 - 5.7

 
 

NA

4

2.6 m

0.0 - 6.9

 

Primary site

Duodenum

71

6.2 m

5.0 - 7.5

<0.01

 

Jejunoileum

20

11.9 m

5.1 - 18.6

 

Histology

WD/MD

44

6.8 m

6.2 - 7.3

0.45

 

Undifferentiated

38

5.1 m

2.3 - 7.9

 
 

Undetermined

9

8.3 m

0.1 - 16.6

 

Initial status

Recurrent

17

10.5 m

4.0 - 17.1

0.21

 

Locally advanced

4

6.8 m

5.9 - 7.8

 
 

Metastatic

70

5.8 m

4.3 - 7.4

 

Primary tumor

Resected

29

11.8 m

3.8 - 19.8

<0.01

 

Still present

62

5.2 m

3.5 - 6.8

 

Number of metastasis

0

4

6.8 m

5.9 - 7.8

0.20

 

1

50

7.1 m

5.8 - 8.4

 
 

≥2

37

5.5 m

2.7 - 8.3

 

Liver metastasis

Yes

39

4.2 m

3.6 - 4.8

<0.01

 

No

52

7.8 m

6.3 - 9.3

 

Peritoneal metastasis

Yes

42

5.9 m

3.7 - 8.0

0.03

 

No

49

8.6 m

5.5 - 11.8

 

IALN metastasis

Yes

41

5.5 m

3.6 - 7.4

<0.01

 

No

50

7.7 m

6.8 - 8.6

 

Lung metastasis

Yes

6

3.1 m

0.0 - 6.9

0.14

 

No

85

6.7 m

5.6 - 7.8

 

Bone metastasis

Yes

3

5.2 m

2.4 - 7.9

0.75

 

No

88

6.6 m

5.7 - 7.5

 

Chemotherapy

(+)

40

11.8 m

4.6 - 19.0

<0.01

 

(-)

51

4.1 m

3.1 - 5.1

 
  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; WD, well-differentiated; MD, moderately differentiated; IALN, intra-abdominal lymph node.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us